Literature DB >> 11150317

Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition.

H K Wayment1, J O Schenk, B A Sorg.   

Abstract

In vitro rotating disk electrode (RDE) voltammetry and in vivo microdialysis were used to characterize dopamine clearance in the rat medial prefrontal cortex (mPFC). RDE studies indicate that inhibition by cocaine, specific inhibitors of the dopamine transporter (DAT) and norepinephrine transporter (NET), and low Na(+) produced a 50-70% decrease in the velocity of dopamine clearance. Addition of the monoamine (MAO) inhibitors, l-deprenyl, clorgyline, pargyline, or in vivo nialamide produced 30-50% inhibition. Combined effects of uptake inhibitors with l-deprenyl on dopamine clearance were additive (up to 99% inhibition), suggesting that at least two mechanisms may contribute to dopamine clearance. Dopamine measured extracellularly 5 min after exogenous dopamine addition to incubation mixtures revealed that most conditions of DAT/NET inhibition did not produce elevated dopamine levels above controls. Inhibition of MAO produced elevated dopamine levels only after long-term, but not short-term, incubation in vitro. Short-term incubation of l-deprenyl combined with DAT and NET uptake inhibitors increased dopamine above control levels, consistent with more than one mechanism of dopamine clearance. Local infusion of pargyline (100 or 300 microm) into the mPFC or striatum via microdialysis produced more pronounced and immediate increases in mPFC dopamine levels compared with striatum. Furthermore, dopamine elevation in the mPFC was not accompanied by a decrease in the dopamine metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid, as found in the striatum. These findings may have revealed a unique mechanism of mPFC dopamine clearance and therefore contribute to the understanding of multiple behaviors that involve mPFC dopamine transmission, such as schizophrenia, drug abuse, and working memory function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150317      PMCID: PMC6762449     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  71 in total

1.  Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys.

Authors:  J X Cai; A F Arnsten
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

2.  Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.

Authors:  S P Butcher; I S Fairbrother; J S Kelly; G W Arbuthnott
Journal:  J Neurochem       Date:  1990-09       Impact factor: 5.372

Review 3.  On some functions of the human prefrontal cortex.

Authors:  A R Damasio
Journal:  Ann N Y Acad Sci       Date:  1995-12-15       Impact factor: 5.691

4.  The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.

Authors:  G Zsilla; P Földi; G Held; A M Székely; J Knoll
Journal:  Pol J Pharmacol Pharm       Date:  1986 Jan-Feb

Review 5.  The frontal cortex-basal ganglia system in primates.

Authors:  S P Wise; E A Murray; C R Gerfen
Journal:  Crit Rev Neurobiol       Date:  1996

6.  Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance.

Authors:  J Zahrt; J R Taylor; R G Mathew; A F Arnsten
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

7.  Prefrontal cortex lesions differentially disrupt cocaine-reinforced conditioned place preference but not conditioned taste aversion.

Authors:  W L Isaac; A J Nonneman; J Neisewander; T Landers; M T Bardo
Journal:  Behav Neurosci       Date:  1989-04       Impact factor: 1.912

8.  Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain.

Authors:  X Wu; R Kekuda; W Huang; Y J Fei; F H Leibach; J Chen; S J Conway; V Ganapathy
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

9.  Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats.

Authors:  T Kato; B Dong; K Ishii; H Kinemuchi
Journal:  J Neurochem       Date:  1986-04       Impact factor: 5.372

10.  Deprenyl alters behavior and caudate dopamine through an amphetamine-like action.

Authors:  C Okuda; D S Segal; R Kuczenski
Journal:  Pharmacol Biochem Behav       Date:  1992-12       Impact factor: 3.533

View more
  34 in total

1.  Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Authors:  Robert W Buchanan; Elaine Weiner; Deanna L Kelly; James M Gold; William R Keller; James A Waltz; Robert P McMahon; David A Gorelick
Journal:  Schizophr Bull       Date:  2014-11-02       Impact factor: 9.306

2.  Prenatal nicotine exposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice.

Authors:  Tursun Alkam; Takayoshi Mamiya; Nami Kimura; Aya Yoshida; Daisuke Kihara; Yuki Tsunoda; Yuki Aoyama; Masayuki Hiramatsu; Hyoung-Chun Kim; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2017-03-23       Impact factor: 4.530

3.  Expression and immunolocalization of the plasma membrane monoamine transporter in the brain.

Authors:  A Dahlin; L Xia; W Kong; R Hevner; J Wang
Journal:  Neuroscience       Date:  2007-04-03       Impact factor: 3.590

4.  Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.

Authors:  Ronald Kuczenski; David S Segal
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

5.  Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics.

Authors:  Britta Haenisch; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

6.  Conditioned task-set competition: Neural mechanisms of emotional interference in depression.

Authors:  Aleks Stolicyn; J Douglas Steele; Peggy Seriès
Journal:  Cogn Affect Behav Neurosci       Date:  2017-04       Impact factor: 3.282

7.  Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent.

Authors:  Ekaterina Boudanova; Deanna M Navaroli; Haley E Melikian
Journal:  Neuropharmacology       Date:  2007-11-22       Impact factor: 5.250

8.  Effects of persistent cocaine self-administration on amygdala-dependent and dorsal striatum-dependent learning in rats.

Authors:  Tomoko Udo; Francisco Ugalde; Nina DiPietro; Howard B Eichenbaum; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 9.  Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.

Authors:  José A Apud; Daniel R Weinberger
Journal:  NeuroRx       Date:  2006-01

10.  Time-of-day differences in dopamine clearance in the rat medial prefrontal cortex and nucleus accumbens.

Authors:  Evan P Sleipness; Heiko T Jansen; James O Schenk; Barbara A Sorg
Journal:  Synapse       Date:  2008-12       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.